H.C. Wainwright Thinks Protalix Biotherapeutics’ Stock is Going to Recover

By Jason Carr

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Protalix Biotherapeutics (NYSE MKT: PLX) today and set a price target of $5. The company’s shares closed yesterday at $0.64, close to its 52-week low of $0.48.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.3% and a 34.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, RegeneRx Biopharmaceuticals Inc, and Biospecifics Technologies Corp.

Protalix Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.

The company has a one-year high of $1.45 and a one-year low of $0.48. Currently, Protalix Biotherapeutics has an average volume of 857K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.